CVS plunges 16% after cutting its guidance and citing 'slowing prescription growth'
Sarah Fortune
"Very recent pharmacy network changes in the marketplace are expected to cause some retail prescriptions to begin migrating out of our pharmacies this quarter," said CEO Larry Merlo in the earnings statement.
"In addition, we are currently experiencing slowing prescription growth in the overall market as well as a soft seasonal business. These factors combined are leading us to reduce the mid-point of our guidance for this year by five cents per share."
In a statement, CVS said it expected full-year adjusted earnings per share between $5.77-$5.83, down from a previously announced range of $5.81-$5.89, and below analysts' estimate for $5.85.
For the third quarter, CBS reported net revenue of $44.6 billion, below the forecast for $45.3 billion according to Bloomberg.
The stock lost 15% this year through the market close on Monday.
Markets Insider
- A couple accidentally shipped their cat in an Amazon return package. It arrived safely 6 days later, hundreds of miles away.
- A centenarian who starts her day with gentle exercise and loves walks shares 5 longevity tips, including staying single
- 2 states where home prices are falling because there are too many houses and not enough buyers
- "To sit and talk in the box...!" Kohli's message to critics as RCB wrecks GT in IPL Match 45
- 7 Nutritious and flavourful tiffin ideas to pack for school
- India's e-commerce market set to skyrocket as the country's digital economy surges to USD 1 Trillion by 2030
- Top 5 places to visit near Rishikesh
- Indian economy remains in bright spot: Ministry of Finance